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1 Introduction
In cancer studies, the main tissue of interest is that of the primary tumour. However, there are many 
circumstances in which additional samples from the same patient may be collected and analysed. 
In whole exome/genome sequencing experiments, normal blood DNA samples from patients are 
often collected in order to determine somatic mutations present in the tumour. In gene expression 
experiments, normal tissue, adjacent to the tumour, is collected and used as a “baseline” sample, 
against which to measure differential gene expression. However, it is not agreed upon whether 
histologically normal tissue from the vicinity of a tumour can be considered entirely normal in the 
strictest sense of the word, as it is reasonable to assume that the molecular profile of such tissue 
will be influenced by the malignant process unfolding in its proximity (see [1, 9] and references 
therein).
In the particular case of survival studies, when both tumour tissue and normal tissue data are 
available, a question that arises is whether normal tissue contains survival signal that is comple-
mentary to that of the tumour tissue. This is a typical example of a paired data setting, where 
there are two data sets available, but only one response vector, and it is unknown which of the 
two data sets is expected to have a stronger predictive ability. Available methods for statistical 
analysis are not tailored to incorporate the full power of having paired data.
Our primary interest is in evaluating the performance of the palasso in comparison to the 
standard and the adaptive lasso in the tumour-normal paired data setting. In this process, we also 
investigate to which extent normal data is more predictive of survival than tumour data.
2 Methods
Paired normal-tumour TCGA RNA-Seq data sets of six cancer types were downloaded from the 
harmonised GDC database ([10]) using the R-package TCGAbiolinks ([4]). In each data set, only 
those genes were retained that had more than two counts per million in at least three samples. 
The data were normalised using the trimmed mean of M-values method (TMM) of the R-package 
edgeR ([11, 12]).
To explore the data, we produced multidimensional scaling plots, and examined the profile of 
p-values resulting from simple Cox proportional hazard regression on each gene, and the p-values 
obtained by applying the global test on the normal and tumour data separately ([6, 7]). Multiple 
testing correction was done using the Benjamini-Hochberg method ([2]).
We compared the Cox palasso to the standard Cox lasso and the adaptive Cox lasso ([5, 13]), 
with weights given by the inverse of the absolute values of the rescaled concordance indices of the 
standardised covariates. The models were each applied to the tumour tissue data, the normal tissue
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data and the pooled data separately. The measure optimised by the cross-validation procedure used
to select the regularisation parameter and weighting scheme is the log partial likelihood deviance.
The cross-validated log partial likelihood for the kth fold is given here by the difference of the
log partial likelihood evaluated on the full data set, and that evaluated on the data set with the
kth fold excluded (see [13], equation (11)). To evaluate the performance of each of the models,
we divided the data of each cancer type into 5 subsets, and used each of these subsets as a test
set for the model trained on the remaining 4 subsets. We then computed the resulting log partial
likelihood deviances as above.
The data were standardised prior to the analysis, and all cross-validation procedures were
performed with five folds, which are fixed across models. For all models, we restricted the maximum
number of non-zero coefficients allowed to 10.
3 Results
The summary of the data sets can be seen in Table 1, giving the number of patients in each cohort,
the number of corresponding events (deaths), and the number of genes retained for analysis.
Full Name of Study
Number of patients
(Number of events)
Number of genes
TCGA-KIRC Kidney renal clear cell carcinoma 71 (25) 18391
TCGA-LUAD Lung adenocarcinoma 56 (22) 19376
TCGA-LIHC Liver hepatocellular carcinoma 49 (30) 16729
TCGA-LUSC Lung squamous cell carcinoma 47 (23) 18842
TCGA-HNSC Head and Neck squamous cell carcinoma 43 (31) 17700
TCGA-BRCA Breast invasive carcinoma 105 (37) 20936
Table 1: Data sets.
The primary tumour data is labelled as “TP”, and the normal tissue data is labelled as “NT”.
As can be expected, there appears to be a substantial amount of differential expression between the
tumour samples and the normal samples. This can be visualised with the help of multidimensional
scaling plots, shown in Figure 3.
To evaluate the strength of the survival signal in the data, we performed simple Cox regression
on each gene, in the tumour data and the normal data separately (Figures 4, 5, 6). We did not
see any pattern as to which data set is more informative with regard to survival across cancer
types (cf. [9]). In the case of TCGA-KIRC both data sets exhibit comparable, relatively strong,
survival signal. For TCGA-LIHC and TCGA-HNSC, normal tissue seems to be more important
for survival, while for TCGA-BRCA it seems to be the tumour tissue that is more important. For
TCGA-LUAD and TCGA-LUSC, none of the data sets seem to contain any survival information.
These results are corroborated to a great extent by the p-values of the global test.
TP min adj p-value NT min adj p-value TP global test NT global test
TCGA-KIRC 0.007 0.002 0.000 0.069
TCGA-LUAD 0.300 1.000 0.033 0.775
TCGA-LIHC 0.312 0.042 0.098 0.023
TCGA-LUSC 1.000 0.276 0.662 0.185
TCGA-HNSC 0.387 0.096 0.124 0.296
TCGA-BRCA 0.181 0.999 0.089 0.851
Table 2: The minimum adjusted p-values obtained from simple Cox regression and the p-values
obtained from the global test.
For each cancer type we compared palasso with 2x3 = 6 standard models: the ordinary lasso
and adaptive lasso as applied on the tumour data, the normal data and the pooled data. We
compared the results by ranking the log partial likelihood deviances, as computed on the left-
out samples using five-fold cross-validation [14]. The model resulting from the fourth weighting
scheme is unique for palasso. If palasso chooses this model during the training phase, we assess its
performance across seven models. Otherwise, palasso is one of the standard adaptive models, in
which case its performance is assessed across six models.
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We also display the performance of palasso on training samples. This allows us to judge from
the training data whether adaptation is deemed useful or not. Note that by definition of palasso,
which contains the 4 adaptive models in its bag, it can only be outperformed by one of the three
lasso models here, so the maximal rank equals 4. We display the results for all five folds (which
are fixed for all models), because different folds may lead to different chosen models, plus it allows
assessing the stability of the results.
Figure 1: Ranks of the palasso models upon training (left), and testing (right). Each symbol
represents the model chosen by palasso. The tumour tissue data is coded as TP and the normal
tissue data is code as NT. The fourth weighting scheme of the palasso is the “within”-scheme.
Ranks in the training are computed out of 4. Ranks in the testing are computed out of 6 or 7. Red
symbols indicate that the model chosen by palasso was the empty model.
The number of non-zero coefficients estimated across all models and all training sets, for each
cancer type, is summarised in Figure 2.
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Figure 2: Histograms of the number of non-zero coefficients across all training sets and all models.
4 Discussion
First, we observe that for most cancer types there is no clear connection between the p-values
from the profiles and the global test (see Table 2) on one side and the predictive performance of
the palasso, lasso and adaptive lasso models on the other side. It seems that for at least 4 out of
6 cancer types, lasso is not able to detect the signal, which is corroborated by Figure 2 showing
that many of the trained models are empty for those types. These results show that palasso is not
a ‘miracle tool’: if the standard lasso models do not perform well, it is unlikely that palasso will
enhance the results.
For KIRC, both the p-value results and the variable selection by lasso models do indicate a
presence of signal. Here, however, palasso does not improve the test performance of the other
lasso models. When comparing the test set results of the adaptive lasso models with those of
their standard counterparts (results not shown) this seems mostly a consequence of the fact that
adaptation does not improve the results. Given that palasso is essentially a bag of adaptive models,
it is no surprise palasso does not outperform the other models for KIRC. For HNSC, the palasso
shows test set results that are somewhat better than average. Here, the adaptive lasso on TP
(tumour tissue) also performs well (average rank across 5 folds: 2; data not shown), so there is no
advantage of pairing. Nevertheless, this can only be observed a posteriori, so the fact that palasso
automatically chooses a model is a practical advantage.
For most of the cancer types, the p-value results suggest that dense models may be a better alter-
native in this setting. Indeed, there is substantial literature devoted to the comparison of different
prediction models for survival from gene expression data, and how to evaluate their performances
[3, 15, 16]. In these comparisons, the lasso is typically outperformed by ridge regression, regardless
of the measure of evaluation. Alternatively, prior aggregation of the gene expression values (e.g. by
using prior information and/or dimension reduction techniques like principle component analysis
or partial least squares) may improve survival prediction [15].
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Figure 3: MDS plots of the pooled data sets: in blue the data points corresponding to normal tissue
and in red the data points corresponding to the tumour tissue.
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Figure 4: Plot of ordered p-values obtained from simple Cox regression for each gene, together with
a scatterplot of the p-values of the genes in the tumour data against those in the normal data.
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Figure 5: Plot of ordered p-values obtained from simple Cox regression for each gene, together with
a scatterplot of the p-values of the genes in the tumour data against those in the normal data.
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Figure 6: Plot of ordered p-values obtained from simple Cox regression for each gene, together with
a scatterplot of the p-values of the genes in the tumour data against those in the normal data.
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